Media Articles Related to Razadyne (Galantamine)
What are the Stages of Alzheimer's Disease?
Source: Seniors / Aging News From Medical News Today [2017.01.11]
Alzheimer’s disease is one of the top causes of death in the U.S., but how quickly can it progress and what is the outlook for people who are diagnosed?
Targeted preventive measures for hip fracture are needed for persons with Alzheimer's disease
Source: Bones / Orthopedics News From Medical News Today [2016.12.07]
The hip fracture risk factors are generally similar among those with and without Alzheimer's disease, according to a recent study from the University of Eastern Finland.
Bone loss may be linked to Alzheimer's disease
Source: Bones / Orthopedics News From Medical News Today [2016.12.02]
A study in a mouse model of Alzheimer's finds a potential link between early bone loss and degeneration in an area of the brain that makes serotonin.
Benzodiazepine and related drug use increases hip fractures in persons with Alzheimer's disease
Source: Bones / Orthopedics News From Medical News Today [2016.11.25]
The use of benzodiazepines and related drugs increases the risk of hip fracture by 43% in persons with Alzheimer's disease, according to a new study from the University of Eastern Finland.
Alzheimer's disease proteins could be at fault for leading cause of vision loss among older people
Source: Eye Health / Blindness News From Medical News Today [2016.11.22]
Research from the University of Southampton gives new insight into possible causes of Age-related Macular Degeneration (AMD), a leading cause of vision loss among people aged 50 and older.
Published Studies Related to Razadyne (Galantamine)
Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for
the treatment of Alzheimer's disease: a systematic review and meta-analysis. 
rivastigmine, and memantine for the treatment of AD... CONCLUSIONS: Cholinesterase inhibitors and memantine are able to stabilize or
The prediction of response to galantamine treatment in patients with mild to
moderate Alzheimer's disease. 
The prediction of efficacy in long-term treatment of acetylcholinesterase
inhibitors (AChEIs) is a major clinical issue, although no consistently strong
predictive factors have emerged thus far... Patients who show improvement of episodic
memory function during the first 4 weeks of galantamine administration may be
likely to particularly benefit from galantamine treatment.
Long-term response to galantamine in relation to short-term efficacy data: pooled analysis in patients with mild to moderate Alzheimer's disease. [2011.03]
BACKGROUND: This analysis aimed to identify an operational, clinically relevant definition of response achieved in short-term clinical trials to support the identification of patients with Alzheimer's disease (AD) who would benefit most from long-term galantamine therapy... CONCLUSIONS: Patients who demonstrate improvement, stability, or limited cognitive decline 2-5 months after reaching maintenance doses of galantamine are more likely to experience continued benefit from long-term galantamine therapy.
Galantamine improves sustained attention in chronic cocaine users. [2011.02]
Chronic cocaine users are known to have cognitive deficits that are predictive of poor treatment response. Whether these deficits improve with medications targeting specific cognitive functions has not been examined in previous studies.
Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. [2011.02]
CONCLUSION: Galantamine showed no ameliorative effects on cognitive measures in this 6month, double-blind study of patients with schizophrenia treated with an assured and stable antipsychotic medication delivery system. Galantamine may not be an appropriate augmentation agent for cognitive impairments in patients with schizophrenia at the dose used. Copyright (c) 2010 Elsevier B.V. All rights reserved.
Clinical Trials Related to Razadyne (Galantamine)
Effect of Galantamine on Smoking Abstinence [Completed]
This is a preliminary open-label study to determine whether a medication called galantamine
(Brand Name: Razadyne) will help smokers quit and whether it reduces cognitive problems that
smokers experience during a quit attempt.
A Study to Show That the Change of Attention Measure is Correlated With the Changes of Caregiver's Burden After Treatment With Galantamine in Patients With Alzheimer's Disease [Completed]
The purpose of this study is to demonstrate that the change of attention measure is
correlated with the changes of caregiver's burden after treatment with galantamine.
Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER) [Completed]
The purpose of the study is to find out if the plasma concentration of galantamine extended
release is changed when BMS-708163 is administered at the same time.
Galantamine Effects on Cognitive Function in Abstinent Cocaine Users [Completed]
To evaluate galantamine's effects on cognitive performance in abstinent cocaine users.
Galantamine, a medication approved for treatment of Alzheimer's disease, is an acetylcholine
esterase inhibitor. Galantamine also directly potentiates nicotine receptors. Both of these
effects may result in improved cognitive performance in a group of subjects known to have
impaired performance in various cognitive tasks.
Galantamine Effects on Nicotine Responses in Smokers [Completed]
This will be a 2-4 week double-blind, placebo-controlled study. Twenty four male and female
smokers will first have two 4-day treatment periods, in which they will be randomized to
galantamine (8 mg/day) or placebo. These treatment periods will be separated by a 3 to 14
day washout period. During the first 3-days of each treatment period, smokers will have
daily clinic visits, where they will receive study medications and any adverse effects from
study medications will be monitored. Starting at 10 p. m. on Day 1 of each treatment period,
subjects will refrain from smoking for approximately 2. 5 days, until the experimental
session on Day 4. Compliance with non-smoking will be verified by CO levels < 10 ppm. During
the experimental sessions, subjects will receive saline or 1. 0 mg/70 kg of nicotine
intravenously in a random, double-blind manner. The sequence of nicotine treatments will be
counterbalanced among subjects such that equal number of subjects will receive saline first
or nicotine first. Following each saline and nicotine treatments, physiological, subjective
and cognitive measurements will be obtained